Roth Methods. Inclusion criteria: RA and concomitant upper gastrointestinal dysfunction of varying degrees and severity and history of intolerance to antiinflammatory medication. All participants continued antacids and a bland diet. A 'number of participants' were reported to have had upper GI bleeding problems prior to entering the study. It was reported that the 35 participants Fourteen participants The authors did not present a list of outcomes to be assessed in the Methods section so it is unclear whether or not there has been selective reporting of outcomes.
The lack of a control group means that it is not possible to know whether the reported outcomes would differ for people with RA without concomitant GI comorbidity. Flow chart of the results of the search strategy, outlining the main reasons for study exclusion. If comparisons of subseries are being made, was there sufficient description of the series and the distribution of prognostic factors?
All sections are selected by default , please select the sections you do not wish to print or use the select or deselect all button to add or remove sections. The data available are protected by copyright and may only be used in accordance with the Terms and Conditions. Downloaded data can only be viewed using Review Manager software. Please note that: data are only available for Cochrane Reviews that contain one or more forest plots; and data in the downloaded RevMan file are editable and therefore the review data can be amended without warning.
I agree to these terms and conditions Download data.
skipimlitexcue.cf If you have a Wiley Online Library institutional username and password, enter them here. Skip to Content Cookies. I accept. Browse Advanced search. Content Language Selection. Your language preference is set to English. Where translations are available, article sections will display in this language. Return to English. Collapse all Expand all. References to studies included in this review Jump to: excluded studies additional references. Roth SH, Boost G. An open trial of naproxen in rheumatoid arthritis patients with significant esophageal, gastric, and duodenal lesions.
Google Scholar. References to studies excluded from this review Jump to: included studies additional references. Adam W.
Alvart R. Multicentre trial of piroxicam in ambulant rheumatology. Ammitzboll F. Fenbufen and Indomethacin in the treatment of rheumatoid arthritis.
A double blind randomised controlled trial of droxicam versus indomehtacin in rheumatoid arthritis. Appelboom T, Franchimont P. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. A comparison of the efficacy and tolerability of lornoxicam and indomethacin in ankylosing spondylithis. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. Burry HC, Sibers R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. Busson M. Cardoe N, Fowler PD.
Celecoxib versus diclofenac and omeprazol in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis CONDOR : a randomised trial. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Melo Gomes JA. The safety of arthrotec in patients with rheumatoid arthritis or osteoarthritis: An assessment of the upper gastrointestinal tract by endoscopy.
Doggrell SA. The safety of lumiracoxib when used in the treatment of arthritis.
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Clinical evaluation of ketoprofen in rheumatoid arthritis. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Dose response and safety study of meloxicam up to Geis GS. Arthrotec: A therapeutic option in the management of arthritis. Graziano FM. Grennan DM. Therapeutic uses of azapropazone.
Howard DLG. Jajic Z, Malaise M. Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Karateev AE. Salicylate hepatotoxicity. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs. Lehtinen K. Lisse JR. Clinical efficacy and safety of naprelan versus naprosyn in the treatment of rheumatoid arthritis.
O'Brien W, Grunwaldt E. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Rahme E, Nedjar H. A retrospective cohort study. Current Medical Research and Opinion ; 2 Longterm fenoprofen therapy in patients with rheumtoid arthritis. Endoscopic evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis.
Seideman P, Eriksson LO. Indomethacin in rheumatoid arthritis.
Inflammatory Arthritis in Clinical Practice is intended primarily as a concise practical handbook for general practitioners, rheumatology doctors in training and. Inflammatory arthritis includes a group of arthritis accompanied by joint pain, swelling, Septic arthritis due to gram-negative bacteria is observed in the setting of trauma or . The initial therapeutic goal is to achieve significant clinical . This book is distributed under the terms of the Creative Commons.
Seissiger L, Dell HD. Comparative clinical trial with a new substance, diftalone, versus indomethacin in 30 patients with rheumatoid arthritis.
Philadelphia, Pa. It is characterized by joint hypertrophy, unlike inflammatory arthritis which is characterized by joint erosion. Higgins a. A clinical trial by Katz et al, suggested that this approach is effective in RA. Depression may be associated with symptoms including an altered appetite, poor sleep, fatigue, lack of concentration and suicidal thoughts.